President/CEO ADNP Kids Research Foundation /ADNPkids.com,SPARK For Autism Advisory Committee, Advocacy Ambassador for Autism Speaks, Mom to Tony (aka Superman)
First-ever clinical trial for rare disorder that is a leading genetic cause of autism also identifies path for a ketamine clinical development program @mattmight@SeaverAutism@SimonsFdn@autismspeaks
https://t.co/giJchHVCfX
Thank you KOIN Extra AM for doing a live interview with me today on Rare Disease Day in DC, and for sharing the challenges faced by parents of children with rare brain diseases.
https://t.co/1xbHqUKqDW
#RareDiseaseDay2023#cureADNP
What the……….?
@amazon is “ending” #AmazonSmile?
Small #raredisease grassroots nonprofits like ours @ADNPkids need every penny we can get, and our family & friends sign up to help us, no you are shutting it down. #AmazonFrown this sucks!
New Study Suggests Ketamine May Be An Effective Treatment for Children with ADNP Syndrome
First-ever clinical trial for rare disorder that is a leading genetic cause of autism also identifies path for a ketamine clinical development program https://t.co/73rCdNymGM
mRNA display makes billions of macrocyclic peptides in one round (🤯) - dramatically impacting drug discovery.
@ACSMedChemLett highlights Merck’s PCSK9 inhibitor which is the first clinical candidate from this technology!
https://t.co/yvZFxi0M0f
LIVE on Gene Fixers w/ @mattmight to discuss drug repurposing, specifically the repurposed drug #ketamine for #ADNP found using Dr. Might’s @ncats_nih_gov funded AI tool.
.
1st #raredisease to start #fda#RepurposedDrug trial using #AI https://t.co/UgdaR5XvY3
.@LynseyChediak is Rarebase’s Head of Partnerships. In our first episode of Rarebase Remarks, learn about Lynsey's own experience with #raredisease and her hopes for research and treatment.
https://t.co/YnJqRApVti
We are so excited to start this amazing project that we hope will help our children. Rare Disease research is funded by families - because we are desperately trying to save our children. Read about how we are stepping into gene therapy for ADNP.